WO2023069461A3 - Method for the prevention and treatment of coronavirus disease - Google Patents

Method for the prevention and treatment of coronavirus disease Download PDF

Info

Publication number
WO2023069461A3
WO2023069461A3 PCT/US2022/047053 US2022047053W WO2023069461A3 WO 2023069461 A3 WO2023069461 A3 WO 2023069461A3 US 2022047053 W US2022047053 W US 2022047053W WO 2023069461 A3 WO2023069461 A3 WO 2023069461A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
treatment
coronavirus disease
coronavirus
disease
Prior art date
Application number
PCT/US2022/047053
Other languages
French (fr)
Other versions
WO2023069461A2 (en
Inventor
Farshad Guirakhoo
Thomas P. Monath
Alexander Rumyantsev
Original Assignee
Vaxxinity, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxxinity, Inc. filed Critical Vaxxinity, Inc.
Publication of WO2023069461A2 publication Critical patent/WO2023069461A2/en
Publication of WO2023069461A3 publication Critical patent/WO2023069461A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Abstract

The present disclosure is directed to methods for preventing or reducing the severity of COVID-19 in subjects in need thereof.
PCT/US2022/047053 2021-10-19 2022-10-18 Method for the prevention and treatment of coronavirus disease WO2023069461A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163257544P 2021-10-19 2021-10-19
US63/257,544 2021-10-19

Publications (2)

Publication Number Publication Date
WO2023069461A2 WO2023069461A2 (en) 2023-04-27
WO2023069461A3 true WO2023069461A3 (en) 2023-06-01

Family

ID=86059605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/047053 WO2023069461A2 (en) 2021-10-19 2022-10-18 Method for the prevention and treatment of coronavirus disease

Country Status (1)

Country Link
WO (1) WO2023069461A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163622A1 (en) * 2020-02-14 2021-08-19 Geovax, Inc. Vaccines and uses thereof to induce an immune response to sars-cov2
WO2021168305A1 (en) * 2020-02-19 2021-08-26 Ubi Ip Holdings Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19)
US20210309733A1 (en) * 2020-03-08 2021-10-07 Humanigen, Inc. Methods for treating coronavirus infection and resulting inflammation-induced lung injury

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163622A1 (en) * 2020-02-14 2021-08-19 Geovax, Inc. Vaccines and uses thereof to induce an immune response to sars-cov2
WO2021168305A1 (en) * 2020-02-19 2021-08-26 Ubi Ip Holdings Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19)
US20210309733A1 (en) * 2020-03-08 2021-10-07 Humanigen, Inc. Methods for treating coronavirus infection and resulting inflammation-induced lung injury

Also Published As

Publication number Publication date
WO2023069461A2 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
JOP20220179A1 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2003099195A3 (en) Immunomodulatory compounds and methods of use thereof
AU7958701A (en) Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2006040688A3 (en) Inhibitors of acetylcholinesterase for treating skin diseases
EP1712239A3 (en) Interleukin-1 inhibitors in the treatment of diseases
AUPQ878600A0 (en) Compositions and methods for the treatment of intact skin
WO2004012762A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
WO2020023530A3 (en) Methods of treatment and prevention of alzheimer's disease
BRPI0414887A (en) methods of treatment, prevention, delay of onset or reduction of effects of proinflammatory cytokines on a mammal and treatment, prevention, delay of onset of a condition associated with an effect of proinflammatory cytokines on a mammal, and, pharmaceutical composition
WO2023069461A3 (en) Method for the prevention and treatment of coronavirus disease
WO2005074566A3 (en) Method of identifying strategies for treatment or prevention of ventricular fibrillation and ventricular tachycardia
WO2004062616A3 (en) Method of treating cognitive decline due to sleep deprivation and stress
ATE378304T1 (en) METHOD AND DEVICE FOR PRODUCING CONCRETE
WO2021195470A3 (en) Identification and use of compounds in the treatment or prevention of severe acute respiratory syndrome coronavirus 2
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
WO2022184930A3 (en) Compositions for the treatment of ebv associated diseases or conditions
WO2023172878A3 (en) Strained skin treatment devices and methods
EP4234022A3 (en) Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
WO2022011271A3 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
WO2020061067A8 (en) Compositions and methods for treating bone injury
WO2007133749A3 (en) Methods and compositions for treating and preventing peripheral nerve damage
WO2024006537A9 (en) Methods for ameliorating cognitive impairment using bile acid derivatives
WO2022251752A3 (en) Dual treatment of migraine
RU2017483C1 (en) Agent for prophylaxis of professional hypoacusis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22884375

Country of ref document: EP

Kind code of ref document: A2